Recent Advancements in the Treatment of Rectal Gastrointestinal Stromal Tumor: In Era of Imatinib

References

• Søreide K, Sandvik OM, Søreide JA, et al. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46. doi:10.1016/j.canep.2015.10.031
   PubMed Web of Science ®Google Scholar
• Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11:865–878. doi:10.1038/nrc3143
   PubMed Web of Science ®Google Scholar
• Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13:265–274. doi:10.1016/s1470-2045(11)70299-6
   PubMed Web of Science ®Google Scholar
• Baik SH, Kim NK, Lee CH, et al. Gastrointestinal stromal tumor of the rectum: an analysis of seven cases. Surg Today. 2007;37:455–459. doi:10.1007/s00595-006-3424-1
   PubMed Web of Science ®Google Scholar
• Jakob J, Mussi C, Ronellenfitsch U, et al. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib. Ann Surg Oncol. 2013;20:586–592. doi:10.1245/s10434-012-2647-1
   PubMed Web of Science ®Google Scholar
• Miettinen M, Furlong M, Sarlomo-Rikala M, et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol. 2001;25:1121–1133. doi:10.1097/00000478-200109000-00002
   PubMed Web of Science ®Google Scholar
• Guo W, Yang Z, Wei Y, et al. Radical excision versus local resection for primary rectal gastrointestinal stromal tumors cohort study. Int J Surg. 2020;77:190–197. doi:10.1016/j.ijsu.2020.03.068
   PubMed Web of Science ®Google Scholar
• Watanabe Y, et al. Clinical outcomes of different therapeutic modalities for rectal gastrointestinal stromal tumor: summary of 14-year clinical experience in a single center. Cancer Sci. 2020;77:1–7. doi:10.1111/cas.1420210.1016/j.ijsu.2020.03.007
   Google Scholar
• Nepal P, Mori S, Kita Y, et al. Management of a case of high-risk gastrointestinal stromal tumor in rectum by transanal minimal invasive surgery. World J Surg Oncol. 2018;16:165. doi:10.1186/s12957-018-1463-x
   PubMed Web of Science ®Google Scholar
• Parks AG, Stuart AE. The management of villous tumours of the large bowel. Br J Surg. 1973;60:688–695. doi:10.1002/bjs.1800600908
   PubMed Web of Science ®Google Scholar
• Pintor-Tortolero J, García JC, Cantero R. Transanal minimally invasive surgery approach for rectal GIST. Tech Coloproctol. 2016;20:321–322. doi:10.1007/s10151-016-1438-2
   PubMed Web of Science ®Google Scholar
• Yang Z, et al. Transanal versus nontransanal surgery for the treatment of primary rectal gastrointestinal stromal tumors: a 10-year experience in a high-volume center. World J Surg Oncol. 2020;8:201. doi:10.1186/s12957-018-1427-110.21037/atm.2020.01.55
   Google Scholar
• Paty PB, Nash GM, Baron P, et al. Long-term results of local excision for rectal cancer. Ann Surg. 2002;236(4):522–529; discussion 529–530. doi:10.1097/00000658-200210000-00015
   Web of Science ®Google Scholar
• Eldamshety O, Metwally IH, Ghoneem E, Elkashef WF. Resection of rectal GIST using a novel technique: a report of two cases. Ecancermedicalscience. 2017;11:760. doi:10.3332/ecancer.2017.760
   PubMed Web of Science ®Google Scholar
• Punnen S, Karimuddin AA, Raval MJ, Phang PT, Brown CJ. Transanal Endoscopic Microsurgery (TEM) for rectal GI stromal tumor. J Surg Oncol. 2021;221:183–186. doi:10.1002/jso.2562110.1016/j.amjsurg.2020.07.013
   Google Scholar
• Bai X, Zhou W, Li Y, Lin G. Transanal endoscopic microsurgery with alternative neoadjuvant imatinib for localized rectal gastrointestinal stromal tumor: a single center experience with long-term surveillance. Surgical endoscopy. 2021;35:3607–3617. doi:10.1007/s00464-020-07837-5
   PubMed Web of Science ®Google Scholar
• Maslekar S, Pillinger SH, Sharma A, Taylor A, Monson JR. Cost analysis of transanal endoscopic microsurgery for rectal tumours. Colorectal Dis. 2007;9:229–234. doi:10.1111/j.1463-1318.2006.01132.x
   PubMed Web of Science ®Google Scholar
• Atallah S, Albert M, Larach S. Transanal minimally invasive surgery: a giant leap forward. Surg Endosc. 2010;24:2200–2205. doi:10.1007/s00464-010-0927-z
   PubMed Web of Science ®Google Scholar
• Matsushima K, Kayo M. Transsacral approach to resect a gastrointestinal stromal tumor in the rectum: report of two cases. Surg Today. 2007;37:698–701. doi:10.1007/s00595-006-3466-4
   PubMed Web of Science ®Google Scholar
• Gervaz P, Huber O, Bucher P, Sappino P, Morel P. Trans-sacral (Kraske) approach for gastrointestinal stromal tumour of the lower rectum: old procedure for a new disease. Colorectal Dis. 2008;10:951–952. doi:10.1111/j.1463-1318.2008.01489.x
   PubMed Web of Science ®Google Scholar
• Qin X, Li C, Yang Z, et al. Transsacrococcygeal approach in rectal gastrointestinal stromal tumour resection: 10-year experience at a single centre. Ann Transl Med. 2021;9:341. doi:10.21037/atm-20-8204
   PubMed Web of Science ®Google Scholar
• Tokunaga R, Sakamoto Y, Nakagawa S, et al. Para-sacral approach for large gastrointestinal stromal tumor of the lower rectum. Int Cancer Conf J. 2018;7:40–42. doi:10.1007/s13691-017-0314-x
   PubMed Web of Science ®Google Scholar
• Matsumi Y, Hamada M, Sakaguchi T, Sekimoto M, Kurokawa H, Kinoshita H. Para-sacral approach followed by laparoscopic low anterior resection of a gastrointestinal stromal tumour at the anterior wall of the lower rectum. Colorectal Dis. 2021;23:1579–1583. doi:10.1111/codi.15597
   PubMed Web of Science ®Google Scholar
• Tulina I, Kitsenko Y, Lukyano A, Bergamaschi R, Tsarkov P. Transperineal Excision of Rectal Gastrointestinal Stromal Tumor. Surg Technol Int. 2019;34:195–198.
   PubMedGoogle Scholar
• Du JL, Chen CC, Chao HM, Kuo LJ. Robot-assisted intersphincteric resection for rectal submucosal tumour. Int J Surg Pathol. 2016;12:478–482. doi:10.1177/106689691877317710.1002/rcs.1667
   Google Scholar
• Hellan M, Maker VK. Transvaginal excision of a large rectal stromal tumor: an alternative. Am J Surg. 2006;191:121–123. doi:10.1016/j.amjsurg.2005.10.013
   PubMed Web of Science ®Google Scholar
• Hara M, Takayama S, Arakawa A, et al. Transvaginal resection of a rectal gastrointestinal stromal tumor. Surg Today. 2012;42:909–912. doi:10.1007/s00595-012-0215-8
   PubMed Web of Science ®Google Scholar
• Shizhuo W, Nannan L, Sha N, et al. Transvaginal excision of rectal stromal tumors: case reports and a literature review. World J Surg Oncol. 2019;17:164. doi:10.1186/s12957-019-1703-8
   PubMed Web of Science ®Google Scholar
• Ferreira MM, Guimaraes N, Monica IB, et al. Transvaginal resection of a rectal gastrointestinal stromal tumor: a case report. J Med Cases. 2021;12:57–60. doi:10.14740/jmc3615
   PubMedGoogle Scholar
• Sun LF, He JJ, Yu S-J, et al. Transsacral excision with pre-operative imatinib mesylate treatment and approach for gastrointestinal stromal tumors in the rectum: a report of two cases. Oncol Lett. 2014;8:1455–1460. doi:10.3892/ol.2014.2406
   PubMed Web of Science ®Google Scholar
• Yanovskiy M, Saddig C, Ommer A, Pahnke JM, Kröpfl D. [Gastrointestinal stromal tumor (GIST) of the anterior rectal wall. R0 resection with simultaneous radical retropubic prostatectomy]. Der Urologe. 2010;49:271–274. German. doi:10.1007/s00120-009-2186-y
   Web of Science ®Google Scholar
• Hamada M, Ozaki K, Horimi T, et al. Recurrent rectal GIST resected successfully after preoperative chemotherapy with imatinib mesylate. Int J Clin Oncol. 2008;13:355–360. doi:10.1007/s10147-007-0735-1
   PubMed Web of Science ®Google Scholar
• Kinoshita H, Sakata Y, Umano Y, Iwamoto H, Mori K. Perineal approach for a gastrointestinal stromal tumor on the anterior wall of the lower rectum. World J Surg Oncol. 2014;12:62. doi:10.1186/1477-7819-12-62
   PubMed Web of Science ®Google Scholar
• Kanesada K, et al. [A case of gastrointestinal stromal tumor of the lower rectum that enabled minimally invasive surgery with imatinib mesylate as neoadjuvant chemotherapy]. Gan To Kagaku Ryoho. 2021;48:269–272. Japanese.
   PubMedGoogle Scholar
• Spinelli A, Carvello M, Sacchi M, et al. Transanal minimally invasive surgery (TAMIS) for anterior rectal GIST. Tech Coloproctol. 2019;23:501–502. doi:10.1007/s10151-019-01979-y
   PubMed Web of Science ®Google Scholar
• Wu X, Lin G, Qiu H, Zhou J, Xu J. [Transanal endoscopic microsurgery for local excision of rectal gastrointestinal stromal tumors]. Zhonghua wei Chang Wai Ke Za Zhi. 2018;21:1296–1300. Chinese.
   PubMedGoogle Scholar
• Liu Q, Zhong G, Zhou W, Lin G. Initial application of transanal endoscopic microsurgery for high-risk lower rectal gastrointestinal stromal tumor after imatinib mesylate neoadjuvant chemotherapy: a case report. Medicine. 2017;96:e7538. doi:10.1097/md.0000000000007538
   PubMed Web of Science ®Google Scholar
• Han X, Xu J, Qiu H, Lin G. A novel curative treatment strategy for patients with lower grade rectal gastrointestinal stromal tumor: chemoreduction combined with transanal endoscopic microsurgery. J Laparoendosc Adv Surg Tech A. 2017;27:579–585. doi:10.1089/lap.2017.0051
   PubMed Web of Science ®Google Scholar
• Kane WJ, Friel CM. Diagnosis and treatment of rectal gastrointestinal stromal tumors. Dis Colon Rectum. 2019;62:537–540. doi:10.1097/dcr.0000000000001376
   PubMed Web of Science ®Google Scholar
• D’Hondt M, Yoshihara E, Dedrye L, et al. Transanal endoscopic operation for benign rectal lesions and T1 carcinoma. J Soc Laparoendosc Surg. 2017;21. doi:10.4293/jsls.2016.00093
   PubMed Web of Science ®Google Scholar
• Sun Q, Su N, Li X, Hu Z, Wang W. Open transanal resection of low rectal stromal tumor following neoadjuvant therapy of imatinib mesylate: report of 11 cases and review of literature. Asia Pac J Clin Oncol. 2020;16:123–128. doi:10.1016/j.amjsurg.2020.07.01310.1111/ajco.13292
   PubMed Web of Science ®Google Scholar
• Ishida T, Furumatsu K, Kado T. Endoscopic submucosal dissection of a rectal gastrointestinal stromal tumor close to the dentate line. Dig Endosc. 2020;32:e49–e51. doi:10.1111/den.13605
   PubMed Web of Science ®Google Scholar
• Wallenhorst T, et al. Endoscopic resection of a rectal gastrointestinal stromal tumor using the submucosal tunneling endoscopic resection (STER) technique. Endoscopy. 2021. doi:10.1055/a-1508-5241
   Web of Science ®Google Scholar
• Hiyoshi Y, Yamasaki A, Shono T, et al. Laparoscopic and endoscopic cooperative surgery for rectal GI stromal tumor. Dis Colon Rectum. 2020;63:116. doi:10.21037/atm.2020.01.5510.1097/dcr.0000000000001514
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–480. doi:10.1056/NEJMoa020461
   PubMed Web of Science ®Google Scholar
• Corless CL, Ballman KV, Antonescu CR, et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J clin oncol. 2014;32:1563–1570. doi:10.1200/jco.2013.51.2046
   PubMed Web of Science ®Google Scholar
• Casali PG, Le Cesne A, Poveda Velasco A, et al. Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European Organisation for research and treatment of cancer soft tissue and bone sarcoma group intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for research on sarcomas. J clin oncol. 2015;33:4276–4283. doi:10.1200/jco.2015.62.4304
   PubMed Web of Science ®Google Scholar
• Kajiura S, Hosokawa A, Nanjyo S, et al. [A case of a gastrointestinal stromal tumor of the rectum effectively treated with continuously-administered regorafenib after failure of imatinib and sunitinib]. Nihon Shokakibyo Gakkai zasshi. 2016;113:655–661. Japanese. doi:10.11405/nisshoshi.113.655
   PubMedGoogle Scholar
• Liu H, Yan Z, Liao G, Yin H. Treatment strategy of rectal gastrointestinal stromal tumor (GIST). J Surg Oncol. 2014;109:708–713. doi:10.1002/jso.23562
   PubMed Web of Science ®Google Scholar
• Wilkinson MJ, Fitzgerald JEF, Strauss DC, et al. Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib. Br J Surg. 2015;102:965–971. doi:10.1002/bjs.9818
   PubMed Web of Science ®Google Scholar
• Hawkins AT, Wells KO, Krishnamurty DM, et al. Preoperative chemotherapy and survival for large anorectal gastrointestinal stromal tumors: a national analysis of 333 cases. Ann Surg Oncol. 2017;24:1195–1201. doi:10.1245/s10434-016-5706-1
   PubMed Web of Science ®Google Scholar
• Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(Suppl 2):ii35–ii38. doi:10.1093/annonc/mdn080
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Gronchi A, Hohenberger P, et al. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol. 2013;20:2937–2943. doi:10.1245/s10434-013-3013-7
   PubMed Web of Science ®Google Scholar
• Lo SS, Papachristou GI, Finkelstein SD, et al. Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: report of a case. Dis Colon Rectum. 2005;48:1316–1319. doi:10.1007/s10350-004-0922-3
   PubMed Web of Science ®Google Scholar
• Alavi K. Expert commentary on the diagnosis and treatment of rectal GI tumors. Dis Colon Rectum. 2019;62:540–541. doi:10.1097/dcr.0000000000001375
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J clin oncol. 2003;21:4342–4349. doi:10.1200/jco.2003.04.190
   PubMed Web of Science ®Google Scholar
• Joensuu H, Rutkowski P, Nishida T, et al. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. J clin oncol. 2015;33:634–642. doi:10.1200/jco.2014.57.4970
   PubMed Web of Science ®Google Scholar
• Kameyama H, Kanda T, Tajima Y, et al. Management of rectal gastrointestinal stromal tumor. Transl Gastroenterol Hepatol. 2018;3:8. doi:10.21037/tgh.2018.01.08
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American intergroup Phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by cancer and leukemia group B and Southwest Oncology Group. J clin oncol. 2008;26:5360–5367. doi:10.1200/jco.2008.17.4284
   PubMed Web of Science ®Google Scholar
• Yang W, Liu Q, Lin G. The effect of neoadjuvant imatinib therapy on outcome and survival in rectal gastrointestinal stromal tumors: a multiinstitutional study. J Surg Oncol. 2021;124(7):1128–1135. doi:10.1002/jso.26628
   PubMed Web of Science ®Google Scholar
• Yong ZZ, et al. Neoadjuvant tyrosine kinase inhibitors in rectal gastrointestinal stromal tumours: a provision for enhanced oncological and functional outcomes. Int J Clin Oncol. 2021;26:913–921. doi:10.1007/s10147-021-01867-2
   PubMed Web of Science ®Google Scholar
• IJzerman NS, Mohammadi M, Tzanis D, et al. Quality of treatment and surgical approach for rectal gastrointestinal stromal tumour (GIST) in a large European cohort. Eur j Surg Oncol. 2020;46:1124–1130. doi:10.1016/j.ejso.2020.02.033
   PubMed Web of Science ®Google Scholar
• Tatsuoka T, et al. Frequent rectal gastrointestinal stromal tumor recurrences in the imatinib era: retrospective analysis of an International Patient Registry. World J Surg Oncol. 2019;120:715–721. doi:10.1186/s12957-017-1231-310.1002/jso.25621
   Google Scholar
• von Mehren M, Randall RL, Benjamin RS, et al. Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2018;16:536–563. doi:10.6004/jnccn.2018.0025
   PubMed Web of Science ®Google Scholar
• Qi J, Liu H-L, Ren F, et al. Preoperative adjuvant therapy for locally advanced and recurrent/metastatic gastrointestinal stromal tumors: a retrospective study. World J Surg Oncol. 2020;18:70. doi:10.1186/s12957-020-01840-9
   PubMed Web of Science ®Google Scholar
• Zanwar S, Ostwal V, Sahu A, et al. Rectal GIST-Outcomes and viewpoint from a tertiary cancer center. Indian j Gastroenterol. 2016;35:445–449. doi:10.1007/s12664-016-0710-8
   PubMedGoogle Scholar
• Akiyoshi T, Ueno M, Fukunaga Y, et al. Laparoscopic local excision and rectoanal anastomosis for rectal gastrointestinal stromal tumor: modified laparoscopic intersphincteric resection technique. Dis Colon Rectum. 2014;57:900–904. doi:10.1097/dcr.0000000000000146
   PubMed Web of Science ®Google Scholar
• Kyo K, Azuma M, Okamoto K, et al. Neoadjuvant imatinib treatment and laparoscopic anus-preserving surgery for a large gastrointestinal stromal tumor of the rectum. World J Surg Oncol. 2016;14:68. doi:10.1186/s12957-016-0837-1
   PubMed Web of Science ®Google Scholar
• Nagano S, Miyoshi N, Takahashi T, et al. Preoperative imatinib and laparoscopic intersphincteric resection for large rectal gastrointestinal stromal tumor: a case report. Int J Surg Case Rep. 2020;71:235–239. doi:10.1016/j.ijscr.2020.05.031
   PubMed Web of Science ®Google Scholar
• Nagakari K, Matoba S, Toda S, et al. Hybrid resection of massive rectal gastrointestinal stromal tumor using laparoscopic and transanal approaches. Asian J Endosc Surg. 2021;14:102–105. doi:10.1111/ases.12824
   PubMed Web of Science ®Google Scholar
• Matsuzuka S, et al. [A case of the large rectal GIST treated by laparoscopic anus preserving operation after neoadjuvant therapy with imatinib mesylate]. Gan To Kagaku Ryoho. 2021;48:385–387. Japanese.
   PubMedGoogle Scholar
• Emoto S, Akiyoshi T, Fukata K, Nagasaki T, Fukunaga Y. Laparoscopic transabdominal dissection and transection of the distal rectum followed by local excision through the anus for rectal gastrointestinal stromal tumor. Dis Colon Rectum. 2020;63:e542. doi:10.1097/dcr.0000000000001814
   PubMed Web of Science ®Google Scholar
• Somu K, Dashore AR, Shah AR, Anandh R. Laparoscopic excision of large lower rectal gastrointestinal stromal tumour (GIST): a case report. J Minim Access Surg. 2016;12:283–285. doi:10.4103/0972-9941.181311
   PubMed Web of Science ®Google Scholar
• Wachter N, Wörns M-A, Dos Santos D, et al. Transanal minimally invasive surgery (TAMIS) approach for large juxta-anal gastrointestinal stromal tumour. J Minim Access Surg. 2016;12:289–291. doi:10.4103/0972-9941.181306
   PubMed Web of Science ®Google Scholar
• Ueki T, Nagayoshi K, Manabe T, et al. Laparoscopic en bloc excision of gastrointestinal stromal tumors of the rectum after neoadjuvant imatinib therapy: anteriorly extended intersphincteric resection combined with partial resection of the prostate. Tech Coloproctol. 2015;19:247–251. doi:10.1007/s10151-014-1261-6
   PubMed Web of Science ®Google Scholar
• Nozawa H, Kanazawa T, Tanaka T, et al. Laparoscopic resection of a gastrointestinal stromal tumor of the lower rectum in a patient with coronary artery disease following long-term neoadjuvant imatinib treatment and anticoagulation therapy. World J Surg Oncol. 2014;12:211. doi:10.1186/1477-7819-12-211
   PubMed Web of Science ®Google Scholar
• Fujimoto Y, Akiyoshi T, Konishi T, et al. Laparoscopic sphincter-preserving surgery (intersphincteric resection) after neoadjuvant imatinib treatment for gastrointestinal stromal tumor (GIST) of the rectum. Int J Colorectal Dis. 2014;29:111–116. doi:10.1007/s00384-013-1769-7
   PubMed Web of Science ®Google Scholar
• Piessen G, et al. Laparoscopic local excision and rectoanal anastomosis for rectal gastrointestinal stromal tumor: modified laparoscopic intersphincteric resection technique. J Surg Oncol. 2014;57:900–904. doi:10.1002/jso.2621510.1097/dcr.0000000000000146
   Google Scholar
• Nakamura T, Mitomi H, Onozato W, et al. Laparoscopic resection of a gastrointestinal stromal tumor of the rectum after treatment with imatinib mesylate: report of a case. Surg Today. 2012;42:1096–1099. doi:10.1007/s00595-012-0134-8
   PubMed Web of Science ®Google Scholar
• Wu X, Li J, Xu W, et al. Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor. Future Oncol. 2018;14:1721–1729. doi:10.2217/fon-2017-0691
   PubMed Web of Science ®Google Scholar
• Fu Y, Hao H, Guo L, Yang G, Zhang X. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor. Oncotarget. 2017;8:10136–10144. doi:10.18632/oncotarget.14359
   PubMedGoogle Scholar
• Joensuu H, Eriksson M, Sundby Hall K, et al. Survival outcomes associated with 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: an analysis of a randomized clinical trial after 10-year follow-up. JAMA oncol. 2020;6:1241–1246. doi:10.1001/jamaoncol.2020.2091
   PubMed Web of Science ®Google Scholar
• Gastrointestinal Stromal Tumor Meta-Analysis Group. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J clin oncol. 2010;28:1247–1253. doi:10.1200/jco.2009.24.2099
   PubMed Web of Science ®Google Scholar
• Ben-Ami E, Barysauskas CM, von Mehren M, et al. Long-term follow-up results of the multicenter Phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol. 2016;27:1794–1799. doi:10.1093/annonc/mdw228
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–1338. doi:10.1016/s0140-6736(06)69446-4
   PubMed Web of Science ®Google Scholar
• Ozols RF, Herbst RS, Colson YL, et al. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening–a report from the American Society of Clinical Oncology. J clin oncol. 2007;25:146–162. doi:10.1200/jco.2006.09.7030
   PubMed Web of Science ®Google Scholar
• Demetri GD, Reichardt P, Kang Y-K, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet. 2013;381:295–302. doi:10.1016/s0140-6736(12)61857-1
   PubMed Web of Science ®Google Scholar
• Demetri GD, Heinrich MC, Fletcher JA, et al. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res. 2009;15:5902–5909. doi:10.1158/1078-0432.ccr-09-0482
   PubMed Web of Science ®Google Scholar
• Blay JY, Serrano C, Heinrich MC, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:923–934. doi:10.1016/s1470-2045(20)30168-6
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. A study of DCC-2618 vs. sunitinib in advanced gist patients after treatment with imatinib (intrigue); 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT03673501. Accessed March 10, 2022.
   Google Scholar
• Wu C, Zhang J, Wu X. Ripretinib in treatment of repeatedly relapsing rectal gastrointestinal stromal tumor: a case report. Ann Palliat Med. 2021;10:4994–4998. doi:10.1002/rcs.166710.21037/apm-21-722
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J clin oncol. 2008;26:5352–5359. doi:10.1200/jco.2007.15.7461
   PubMed Web of Science ®Google Scholar
• Network NCC. NCCN guidelines version 2.2017 soft tissue sarcoma; 2017. Available from: https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed March 10, 2022.
   Google Scholar
• Heinrich MC, Jones RL, von Mehren M, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, Phase 1 trial. Lancet Oncol. 2020;21:935–946. doi:10.1016/s1470-2045(20)30269-2
   PubMed Web of Science ®Google Scholar
• Trullas-Jimeno A, Delgado J, Garcia-Ochoa B, et al. The EMA assessment of avapritinib in the treatment of gastrointestinal stromal tumours harbouring the PDGFRA D842V mutation. ESMO open. 2021;6:100159. doi:10.1016/j.esmoop.2021.100159
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. PLX9486 as a single agent and in combination with PLX3397 or PLX9486 with sunitinib in patients with advanced solid tumors; 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT02401815?term=NCT02401815&draw=2&rank=1. Accessed March 10, 2022.
   Google Scholar
• Trent J, Chugh R, Tsiatis AC, et al. The potent and selective KIT inhibitor PLX9846 dosed in combination with sunitinib demonstrates promising PFS in patients with advanced GIST: final results of phase I/II study. CTOS Virtual Annual Meeting; 2020.
   Google Scholar
• Balachandran VP, Cavnar MJ, Zeng S, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011;17:1094–1100. doi:10.1038/nm.2438
   PubMed Web of Science ®Google Scholar
• Chi P, Qin L-X, Kelly CM, et al. A phase II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with untreated advanced gastrointestinal stromal tumor (GIST). J Clin Oncol. 2020;38(15_suppl):11508. doi:10.1200/JCO.2020.38.15_suppl.11508
   Web of Science ®Google Scholar
• Vincenzi B, Nannini M, Badalamenti G. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. Ther Adv Med Oncol. 2018;10:1758835918794623. doi:10.1177/1758835918794623
   Web of Science ®Google Scholar
• Shen C, Chen H, Yin Y, et al. Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor. Clinics. 2014;69:758–762. doi:10.6061/clinics/2014(11)09\\
   PubMed Web of Science ®Google Scholar
• Bischof DA, Kim Y, Blazer DG, et al. Surgical management of advanced gastrointestinal stromal tumors: an international multi-institutional analysis of 158 patients. J Am Coll Surg. 2014;219:439–449. doi:10.1016/j.jamcollsurg.2014.02.037
   PubMed Web of Science ®Google Scholar
• Choudhury A, Zhao H, Jalali F, et al. Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol Cancer Ther. 2009;8(1):203–213. doi:10.1158/1535-7163.mct-08-0959
   PubMed Web of Science ®Google Scholar
• Di Scioscio V, Greco L, Pallotti MC, et al. Three cases of bone metastases in patients with gastrointestinal stromal tumors. Rare Tumors. 2011;3(2):e17. doi:10.4081/rt.2011.e17
   PubMedGoogle Scholar
• Tezcan Y, Koç M. Gastrointestinal stromal tumor of the rectum with bone and liver metastasis: a case study. Med Oncol. 2011;28(Suppl 1):S204–S206. doi:10.1007/s12032-010-9697-7
   PubMed Web of Science ®Google Scholar
• Pollock J, Morgan D, Denobile J, Williams J. Adjuvant radiotherapy for gastrointestinal stromal tumor of the rectum. Dig Dis Sci. 2001;46:268–272. doi:10.1023/a:1005581000712
   PubMed Web of Science ®Google Scholar